Furthermore, several molecular therapies targeting immune checkpoints, epidermal growth factor receptor (EGFR), tyrosine kinases and cell cycle mediators have been developed in recent years, Nevertheless, the overall 5-year survival rate of NSCLC patients remains less than 14% [3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.